Clinical trials: Patient
Patient Indicated for an ICD
TRUST: Lumos-T Safely RedUceS RouTine Office Device Follow-up
This study is a multi-center, prospective and randomized trial. The primary objective of this study is to demonstrate that the use of the BIOTRONIK Home Monitoring system (HM) can safely reduce the number of regularly scheduled…
- Trial name
- TRUST (NCT00336284)
- Testing
- Home Monitoring, In-Office Conventional Follow-up
- Where
- 110 sites in United States, Canada
- Volunteers
- 1,450 people
- Sponsor
- Biotronik, Inc.
Suction Catheter Bioburder Level After Patient Use.
Study the Average Aerobic Bioburden Levels on Catheters After Use With Egret Catheter and the Predicate Device
PURPOSE OF EVALUATION: This study will verify \& validate the acceptability of Egret's extended use product as compared to the existing daily change-out product.
- Trial name
- NCT01124578
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Egret Medical Products Inc.
Respiratory Tract Infections
Compliance And Safety Study In Children With Upper And Lower Respiratory Tract Infections
The objective of this study was to obtain data on the safety, tolerability and compliance with Zithromax in children with bacterial infections of the upper and lower respiratory tract.
- Trial name
- COMPAS (NCT00939185)
- Testing
- Azithromycin
- Volunteers
- 400 people
- Sponsor
- Pfizer
Crohn's Disease, Ulcerative Colitis
An Investigational Study to Test Usability of the Electronic Dosing Equipment Medicpen
This is a study of the electronical dosing tool MedicPen and it's qualities with regards to user friendliness and medication compliance.
- Trial name
- NCT00917514
- Where
- Sweden
- Volunteers
- 25 people
- Sponsor
- Medicpen AB
Frail Elderly, Medication Errors
MD.2 Medication Dispenser Medication Adherence Study
The objective of this study is to quantify the benefits of using the MD.2 on health outcomes.
- Trial name
- NCT00560001
- Testing
- MD.2 Medication Dispenser
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Interactive Medical Developments
ICU Patient
Study of Antibiotic Utilization Measures and Control of ESBLs in China
A single-center, prospective, comparative, antibiotic intervention study for patients admitted to MICU1 and MICU2
- Trial name
- NCT00488813
- Testing
- Third generation cephalosporins
- Volunteers
- 300 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Asthma
Symbicort SMART (Symbicort Maintenance And Reliever Therapy)
The purpose of this study is to investigate the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy.
- Trial name
- SMART (NCT00523679)
- Where
- 3 sites in South Korea
- Volunteers
- 2,000 people
- Sponsor
- AstraZeneca
Epilepsy
Valproate Sustained Release Minitablets (Orfiril(R) Long) Once Daily in the Evening
Valproate is the first line therapy in primary generalized seizures. The applied drug contains sodium valproate in sustained release minitablets.
- Trial name
- NCT00870688
- Testing
- sodium valproate
- Volunteers
- 82 people
- Sponsor
- Desitin Arzneimittel GmbH
New Strategies, GINA 2006
Opinion of Patients Under Treatment That Meets the Criteria of New Treatment Strategy According to GINA 2006
Cross-sectional, one visit study. All the data will be collected through questionnaires. Descriptives statistics will be applied to the data. 832 patients will participate to the study and 104 physicians.
- Conditions
- New Strategies, GINA 2006, Patient Opinion
- Trial name
- EPAGGELIA (NCT00695357)
- Where
- 31 sites in Greece
- Volunteers
- 832 people
- Sponsor
- AstraZeneca
Hypercholesterolemia
Rosuvastatin ORBITAL Germany
The primary objective of the study is to compare the effect of rosuvastatin therapy plus compliance initiatives and rosuvastatin therapy alone for 12 months (52 weeks) on long-term cumulative direct and indirect disease-related…
- Trial name
- NCT00379249
- Testing
- Rosuvastatin
- Volunteers
- 8,000 people
- Sponsor
- AstraZeneca
Primary Hypercholesterolaemia
ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
24 week open label study to compare the treatment either with rosuvastatin or rosuvastatin plus initiatives to improve compliance.
- Trial name
- NCT00396240
- Testing
- Rosuvastatin, Initiatives to improve compliance
- Volunteers
- 1,294 people
- Sponsor
- AstraZeneca
Kidney Disease
Aranesp® Monthly Preference Study - 2
The purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).
- Trial name
- NCT00117078
- Testing
- Aranesp®
- Sponsor
- Amgen
Gastroesophageal Reflux Disease, GERD
What is the Predictive Value of the Reflux Impact Scale
Gastric distress is a common phenomenon in our society. Heartburn and regurgitation occur daily in about 7% of the adult population,weekly 14-20% pf the adults and monthly in 34-44% of adults.
- Conditions
- Gastroesophageal Reflux Disease, GERD, Heartburn, Acid Regurgitation
- Trial name
- PREDICT (NCT00536328)
- Volunteers
- 938 people
- Sponsor
- AstraZeneca
Patient Comfort, Lens Cleanliness
Comfort and Cleaning Evaluation of Multipurpose Solutions in Contact Lens Patients
To compare patient comfort and overall lens cleanliness with consecutive use of two multipurpose lens solutions.
- Trial name
- NCT00519948
- Testing
- new MPS, opti-free express no rub MPS
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Innovative Medical
Hypertension
Efficacy of the New Closure Device in Improving Patient Compliance in Treatment of Hypertension With Valsartan+/-Hydrochlorothiazide (HCTZ) at 6 Months
This study will evaluate the efficacy of the reminder device Remind Cap® in improving patients' compliance in the consumption of Valsartan +/- Hydrochlorothiazide (HCTZ) in the treatment of hypertension
- Trial name
- NCT00487123
- Testing
- Valsartan+/- Hydrochlorothiazide
- Where
- Singapore
- Sponsor
- Novartis
Essential Hypertension
Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide
The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e.
- Trial name
- CoCa (NCT00608153)
- Volunteers
- 1,773 people
- Sponsor
- AstraZeneca
HIV Infections
A Study of Two Anti-HIV Drug Combinations
The purpose of this study is to compare the safety and effectiveness of taking lamivudine (3TC) plus zidovudine (ZDV) plus a protease inhibitor (PI) with taking the 3TC/ZDV combination tablet (Combivir) plus a PI.
- Trial name
- NCT00002203
- Testing
- Lamivudine/Zidovudine, Lamivudine, Zidovudine
- Where
- 7 sites in United States, Puerto Rico
- Sponsor
- Glaxo Wellcome
HIV Infections
A Study of Combivir Plus Abacavir Plus 141W94 in Patients Who Previously Have Used Anti-HIV Drugs
The purpose of this study is to test the effectiveness of Combivir plus abacavir plus 141W94 in patients who previously have used anti-HIV drugs.
- Trial name
- NCT00002217
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate, Amprenavir
- Where
- United States
- Sponsor
- Glaxo Wellcome
HIV Infections
The Effect of Teaching HIV-Infected Patients About HIV and Treatment
The purpose of this study is to see if an HIV-education course can help under-represented, HIV-infected patients. This study examines the areas of faithfulness to drug regimen, level of HIV in the blood, and health status.
- Trial name
- NCT00002409
- Testing
- Lamivudine/Zidovudine, Abacavir sulfate
- Where
- 25 sites in United States
- Volunteers
- 200 people
- Sponsor
- Glaxo Wellcome